Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. - Wikidata - awgldk - TriplyDB

Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure.

Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure.

http://www.wikidata.org/entity/Q35964249

about

Micro-RNA-195 and -451 regulate the LKB1/AMPK signaling axis by targeting MO25 Inhibition of microRNA function by antimiR oligonucleotides Diagnostic, Prognostic, and Therapeutic Value of Circulating miRNAs in Heart Failure Patients Associated with Oxidative Stress The Role of p38 MAPK in the Development of Diabetic Cardiomyopathy Epigenetics in heart failure phenotypes MicroRNA and Heart Failure Novel epigenetic-based therapies useful in cardiovascular medicine Cardiac Extracellular Vesicles in Normal and Infarcted Heart Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction Epigenetic associations in relation to cardiovascular prevention and therapeutics Epigenetic regulation in cardiac fibrosis Emerging Roles for MicroRNAs in Perioperative Medicine MicroRNAs Based Therapy of Hypertrophic Cardiomyopathy: The Road Traveled So Far 'Micro-managers' of hepatic lipid metabolism and NAFLD Update on the Pathogenic Implications and Clinical Potential of microRNAs in Cardiac Disease The function of miRNA in cardiac hypertrophy MicroRNAs in the Stressed Heart: Sorting the Signal from the Noise Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor Adeno-associated virus-mediated microRNA delivery and therapeutics Epigenetics and miRNA emerge as key regulators of smooth muscle cell phenotype and function MicroRNAs in heart failure: Small molecules with major impact Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology Novel insights into miRNA in lung and heart inflammatory diseases MicroRNAs in stress signaling and human disease Differential expression of microRNAs in different disease states.Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline Heart failure: advanced development in genetics and epigenetics Epigenetic mechanisms in heart development and disease Noncoding RNA in age-related cardiovascular diseases MicroRNAs in cardiovascular disease: an introduction for clinicians Translational Regulation of the Mitochondrial Genome Following Redistribution of Mitochondrial MicroRNA in the Diabetic Heart A cardiac microRNA governs systemic energy homeostasis by regulation of MED13 Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseases Pigmy MicroRNA: surveillance cops in Therapies kingdom microRNA in the development of diabetic complications.Molecular inotropy mediated by cardiac miR-based PDE4D/PRKAR1α/phosphoprotein signaling Distinctive profile of IsomiR expression and novel microRNAs in rat heart left ventricle.Identification of micro-RNA networks in end-stage heart failure because of dilated cardiomyopathy.Anti-miR-148a regulates platelet FcγRIIA signaling and decreases thrombosis in vivo in mice.Current Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure.

P2860

Q21134128-65822805-7B62-4B7E-9EF2-202820A97818 Q21198757-1D7315ED-09F5-47B2-895F-779AE49D22AD Q26744498-B2D33A2D-0666-4337-80D0-FFC53C6F51E6 Q26744743-2B6C8751-C9FF-4222-800C-8B8AED5C0707 Q26747565-B0C318EE-56D5-4818-8719-155866379614 Q26750638-F662D059-BFAE-4C84-94D5-5D7F026314D2 Q26765152-CEC526D1-261C-484D-906C-F13117F85724 Q26770294-ACCF7CC7-5EFE-4B67-AAA6-2F6D6A8B705F Q26771125-2492310D-3786-4CF1-A506-21D740465EBF Q26771428-664470DD-918A-468A-922D-5E69213D0190 Q26774536-50F367F0-79BC-45C3-8F57-CCA08224F52B Q26775176-05E82F66-188D-4E60-B5C4-46639D7F7F4B Q26778555-AA79C753-BF65-4E28-A748-1590A4C1EBD9 Q26801228-96F59056-EF10-44F9-A020-C4D6EA7E4212 Q26801907-9B0B546F-664A-4784-B29B-9CD9EE317211 Q26828961-DC1EF80A-8563-458C-AC7C-36BE1D7A6313 Q26995334-22465BAA-BF4E-429D-B144-42B5CD69B844 Q26996693-FF5B5941-9887-404C-AAE2-5241D33EDE92 Q27005597-41D3459B-3BA4-4B78-8DC4-F19688E4246C Q27006515-0A0227DF-95E9-4A5D-95F6-ABBA4B64049C Q27024714-FB52BDF1-1252-4D57-999F-321FA124424A Q27024879-9348EB7E-EEA8-4973-B401-0E8B15D82224 Q27026348-D9C409B9-66E8-444C-82A9-06B61A02F3F8 Q27027517-45A5AB76-9443-47CC-99F4-FC1270448CEF Q27693279-44A8DA9B-3DFA-4DE6-A736-017E1F75D781 Q27694686-910ED40E-AD41-4F56-9AE7-152EAEEBC61E Q28080771-8BAE6A15-6907-43EB-8DB0-B70EF4363BD6 Q28081134-A3DB6582-AAD5-467E-9DFD-352572FDA798 Q28081466-E31373B5-5D56-4C78-85AA-6D990BF1536C Q28084229-ECEE7A66-6534-4F13-B956-BC92BCD16409 Q28396541-E8478C85-04DF-4B49-BC9C-67050A68D836 Q28505950-B778987B-BDBF-494E-BDCB-854B1494F08E Q28583018-7A3FA5FA-E0E1-41A6-B32C-7E4B3EE08D17 Q28818470-56883A55-32D2-463A-AC0F-165080311DF0 Q30353835-3A00057D-826A-405F-87F4-D8433FD18EC5 Q30828261-CC38D462-6E3D-4241-8366-3C7CB497713A Q31120462-11EB4BC3-5075-485F-8F7E-37F6A3FB78BE Q31136713-A76CF543-9CC2-4615-9D4E-2DA8332CDF71 Q33427174-FFF01BB1-C94E-4B09-9D75-CA18B4BF5D95 Q33595504-C770929F-15A8-4C83-9A99-9ECC6D4A72B7

P2860

Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure.

http://www.wikidata.org/entity/Q35964249

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Therapeutic inhibition of miR- ...... survival during heart failure.

@ast

Therapeutic inhibition of miR- ...... survival during heart failure.

@en

type

label

Therapeutic inhibition of miR- ...... survival during heart failure.

@ast

Therapeutic inhibition of miR- ...... survival during heart failure.

@en

prefLabel

Therapeutic inhibition of miR- ...... survival during heart failure.

@ast

Therapeutic inhibition of miR- ...... survival during heart failure.

@en

P1433

Q35964249-FFACDA14-9755-483D-81A5-7D95A1464850

P1476

Q35964249-901A8582-E5E0-4F40-B8A8-28411F93634C

P2093

Q35964249-00274562-5FDB-4780-871D-C8CE45D8CA48

Q35964249-3A1F8AE7-F2CE-456C-BFE5-D188C4A2A393

Q35964249-8AA9686D-B646-4124-9510-7CA7AFDC4C87

Q35964249-AF536E08-ACBE-4DC6-804E-BC1047236C39

Q35964249-B04CAF87-BAD3-4806-BCA0-19C61482BD4F

Q35964249-BF10F8FC-639C-42D4-9DFA-353EB0ACEAB6

Q35964249-C08059D0-4525-4ED2-9EE7-2BE4E429DC67

Q35964249-EAC98A47-1311-4571-B7CB-D26C06CEFDD3

Q35964249-EB49B7C1-74FB-45F2-9E5D-229CAEB27AE7

Q35964249-EE977324-DF8E-455C-B59B-28AD34F2A7FD

P2860

Q35964249-0D529C28-859B-4797-8E00-87177EE9602A

Q35964249-20354300-92AD-4E27-93DB-AA16DE5BBB4C

Q35964249-22F85FC7-2AD7-4C22-BC87-5808412938E7

Q35964249-2F9F9458-C37A-4166-BA50-A7CEE6606BA3

Q35964249-3DB71F12-99A0-4E01-AF09-DE993867FA37

Q35964249-3ECF67B3-AC05-45B3-BA48-7AA293AB2D84

Q35964249-3EEED308-3EFE-4362-AD26-BE9113FB18FA

Q35964249-507D20A3-6C36-424B-B636-479E73755000

Q35964249-59062B64-A096-4199-ABC4-003DAEFEB9F0

Q35964249-5ED092F4-5BCB-4229-A838-E4876912C6EF

P304

Q35964249-07D5D828-A4AB-40A5-A8CD-D8F6A131EA63

P31

Q35964249-ED0BC88C-60EB-41B9-A9EA-AACBD5DC8B71

P356

Q35964249-D91BB5D2-03A9-4CF7-B3BF-D88340E39AC8

P407

Q35964249-AE48491F-ACEA-4D93-882C-0D34FFD83A84

P433

Q35964249-712D94E2-1037-4CE4-BCC3-0F9059DC2003

P478

Q35964249-B0011238-EA4D-42CA-A4B9-325B671CF6EE

P577

Q35964249-BA21BCD9-F2ED-4D99-9DE7-165E1BC0EB4C

P698

Q35964249-6A1FCCB5-3BDC-42E6-A53C-F019D601E1E1

P921

Q35964249-76FA0D96-E6F3-40E5-8CF8-39EA2710B2AD

P932

Q35964249-6A02CB9C-8C79-4DEA-BAF5-C5E6BC375A11

P356

CIRCULATIONAHA.111.030932

P1433

P1476

Therapeutic inhibition of miR- ...... survival during heart failure.

@en

P2093

Anita G Seto

http://www.w3.org/2001/XMLSchema#string

Brent A Dickinson

http://www.w3.org/2001/XMLSchema#string

Christianna Stack

http://www.w3.org/2001/XMLSchema#string

Eric N Olson

http://www.w3.org/2001/XMLSchema#string

Eva van Rooij

http://www.w3.org/2001/XMLSchema#string

Hillary M Semus

http://www.w3.org/2001/XMLSchema#string

Joshua M Lynch

http://www.w3.org/2001/XMLSchema#string

Paul A Latimer

http://www.w3.org/2001/XMLSchema#string

Rusty L Montgomery

http://www.w3.org/2001/XMLSchema#string

Thomas G Hullinger

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating microRNAs are new and sensitive biomarkers of myocardial infarction

A mammalian microRNA expression atlas based on small RNA library sequencing

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver

Silencing of microRNAs in vivo with 'antagomirs'

Myosin heavy chain isoform expression in the failing and nonfailing human heart

Control of stress-dependent cardiac growth and gene expression by a microRNA

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

LNA-mediated microRNA silencing in non-human primates

A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance

MicroRNAs add a new dimension to cardiovascular disease

P304

1537-1547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.111.030932

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21900086

http://www.w3.org/2001/XMLSchema#string

P921

P932

3353551

http://www.w3.org/2001/XMLSchema#string